Announcement • Jul 22
Orbus Neich Medical Group Holdings Limited Announces First Patient Enrollment in Japan Clinical Trial for Proprietary Drug-Coated Balloon Orbus Neich Medical Group Holdings Limited made this announcement on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group. The board of directors of the Company announced the successful enrollment of the first patient in its pivotal Japanese clinical trial (OM-0031). This trial will evaluate the Group’s proprietary coronary paclitaxel drug-coated balloon (DCB), marking a significant step forward for the Group in further consolidating its position in Japan’s interventional cardiology market through its diversified product portfolio. Built upon the Group’s balloon platform, the innovative drug-coated balloon is engineered for deliverability, allowing interventionalists to navigate complex and severely stenotic lesions. The device adopts the Group’s proprietary drug-coating technology, which enables efficient and uniform paclitaxel transfer onto the arterial wall. This technical pairing ensures precise therapeutic dosing and supports vascular healing while maintaining trackability and crossability. By delivering anti-proliferative medicine non-invasively without leaving a permanent implant, the device addresses clinical needs in interventional cardiology. The OM-0031 clinical trial is a prospective, multi-center study designed to evaluate the safety and efficacy of the DCB. The trial targets patients suffering from coronary artery disease, with a focus on the treatment of de novo lesions in both small and large vessels and in-stent restenosis (ISR). The primary endpoint of the study will evaluate target lesion failure (TLF) at the six-month follow-up. Patient enrollment of OM-0031 is expected to continue across 25 cardiovascular centers throughout Japan, with the goal of completing patient enrollment by the end of 2027. Following the follow-up period and data analysis, the Company plans to use the clinical data to support its regulatory submission to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), with the aim of bringing this treatment option to the Japanese market. Recent Insider Transactions • Jun 20
Key Executive recently bought HK$100k worth of stock On the 16th of June, Wing Shing Chen bought around 25k shares on-market at roughly HK$4.00 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Wing Shing's only on-market trade for the last 12 months. Announcement • Jun 09
OrbusNeich Medical Group Holdings Limited Approves Final Dividend for the Year Ended December 31, 2025, Payable on or Around June 26, 2026 OrbusNeich Medical Group Holdings Limited at its AGM held on June 8, 2026 approved the payment of a final dividend of 12 Hong Kong cents per share out of the share premium account of the Company for the year ended December 31, 2025. The final dividend is expected to be distributed in cash on or around June 26, 2026 to the Shareholders whose names appear on the Company's register of members on June 16, 2026, being the record date of determination of entitlements of the Final Dividend. Upcoming Dividend • Jun 03
Upcoming dividend of HK$0.12 per share Eligible shareholders must have bought the stock before 10 June 2026. Payment date: 26 June 2026. Payout ratio is a comfortable 30% but the company is paying out more than the cash it is generating. Trailing yield: 2.8%. Lower than top quartile of Hong Kong dividend payers (6.9%). Lower than average of industry peers (3.4%). Valuation Update With 7 Day Price Move • May 11
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to HK$4.50, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 22x in the Medical Equipment industry in Hong Kong. Total loss to shareholders of 62% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at HK$8.85 per share. Reported Earnings • Apr 17
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: US$0.051 (up from US$0.048 in FY 2024). Revenue: US$180.5m (up 10.0% from FY 2024). Net income: US$41.9m (up 5.5% from FY 2024). Profit margin: 23% (in line with FY 2024). Revenue missed analyst estimates by 3.1%. Earnings per share (EPS) also missed analyst estimates by 3.8%. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Medical Equipment industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings. Declared Dividend • Mar 14
Final dividend of HK$0.12 announced Shareholders will receive a dividend of HK$0.12. Ex-date: 10th June 2026 Payment date: 26th June 2026 Dividend yield will be 7.1%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is covered by earnings (26% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 2 years, but has still been somewhat stable with no excessively large reductions to payments. EPS is expected to grow by 66% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Mar 13
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: US$0.051 (up from US$0.048 in FY 2024). Revenue: US$180.5m (up 10.0% from FY 2024). Net income: US$41.9m (up 5.5% from FY 2024). Profit margin: 23% (in line with FY 2024). Revenue missed analyst estimates by 3.1%. Earnings per share (EPS) also missed analyst estimates by 3.8%. Revenue is forecast to grow 6.2% p.a. on average during the next 2 years, compared to a 26% growth forecast for the Medical Equipment industry in Hong Kong. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings. Announcement • Mar 12
OrbusNeich Medical Group Holdings Limited, Annual General Meeting, Jun 08, 2026 OrbusNeich Medical Group Holdings Limited, Annual General Meeting, Jun 08, 2026. Announcement • Mar 02
OrbusNeich Medical Group Holdings Limited to Report Fiscal Year 2025 Results on Mar 12, 2026 OrbusNeich Medical Group Holdings Limited announced that they will report fiscal year 2025 results on Mar 12, 2026 Announcement • Jan 22
Orbusneich Medical Group Holdings Limited Announces Resignation of Non-Executive Director Zhou Yi, Effective January 22, 2026 OrbusNeich Medical Group Holdings Limited announced that Dr. Zhou Yi has resigned as Non-executive Director of the Company with effect from January 22, 2026 due to his intention to devote more time to his other business commitments. Dr. Zhou has confirmed that he has no disagreement in any respect the Board and that there is no matter in respect of his resignation which needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited. As of January 22, 2026, the Board comprises Mr. David Chien, Ms. Kwai Ching Denise Lau and Mr. Wing Shing Chen as Executive Directors; Mr. Ting San Peter Lionel Leung as Non-executive Director; and Mr. Yip Keung Chan, Mr. Ka Keung Lau BBS, MH, JP and Dr. Lai Fan Gloria Tam as Independent Non-executive Directors. New Risk • Dec 05
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 2.6% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (32% accrual ratio). Minor Risk Paying a dividend despite having no free cash flows. Upcoming Dividend • Sep 11
Upcoming dividend of HK$0.15 per share Eligible shareholders must have bought the stock before 18 September 2025. Payment date: 06 October 2025. Payout ratio is a comfortable 26% but the company is not cash flow positive. Trailing yield: 2.2%. Lower than top quartile of Hong Kong dividend payers (6.6%). In line with average of industry peers (2.2%). Reported Earnings • Aug 17
First half 2025 earnings released: EPS: US$0.024 (vs US$0.023 in 1H 2024) First half 2025 results: EPS: US$0.024 (up from US$0.023 in 1H 2024). Revenue: US$83.6m (up 5.9% from 1H 2024). Net income: US$19.8m (up 5.1% from 1H 2024). Profit margin: 24% (in line with 1H 2024). Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Medical Equipment industry in Hong Kong. Announcement • Aug 04
OrbusNeich Medical Group Holdings Limited to Report First Half, 2025 Results on Aug 15, 2025 OrbusNeich Medical Group Holdings Limited announced that they will report first half, 2025 results on Aug 15, 2025 Valuation Update With 7 Day Price Move • Jul 28
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to HK$5.07, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 18x in the Medical Equipment industry in Hong Kong. Total returns to shareholders of 61% over the past year. Simply Wall St's valuation model estimates the intrinsic value at HK$8.95 per share. Announcement • May 27
Orbusneich Medical Group Holdings Limited Approves Payment of Final Dividend for Year Ended December 31, 2024 OrbusNeich Medical Group Holdings Limited at Annual General Meeting held on May 27, 2025 the company approved and declare the payment of a final dividend of HK10 cents per share out of the share premium account of the Company for the year ended December 31, 2024. Upcoming Dividend • May 22
Upcoming dividend of HK$0.10 per share Eligible shareholders must have bought the stock before 29 May 2025. Payment date: 16 June 2025. Payout ratio is a comfortable 27% but the company is paying out more than the cash it is generating. Trailing yield: 2.6%. Lower than top quartile of Hong Kong dividend payers (7.7%). In line with average of industry peers (2.8%). Valuation Update With 7 Day Price Move • Apr 25
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to HK$4.07, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 15x in the Medical Equipment industry in Hong Kong. Total returns to shareholders of 8.6% over the past year. Reported Earnings • Apr 18
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2024 results: EPS: US$0.048 (down from US$0.054 in FY 2023). Revenue: US$164.1m (up 6.6% from FY 2023). Net income: US$39.7m (down 12% from FY 2023). Profit margin: 24% (down from 29% in FY 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) missed analyst estimates by 2.9%. Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in Hong Kong. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to HK$3.45, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 14x in the Medical Equipment industry in Hong Kong. Total returns to shareholders of 11% over the past year. Major Estimate Revision • Mar 14
Consensus EPS estimates fall by 13% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$186.7m to US$182.2m. EPS estimate also fell from US$0.059 per share to US$0.051 per share. Net income forecast to grow 12% next year vs 49% growth forecast for Medical Equipment industry in Hong Kong. Consensus price target up from HK$4.98 to HK$5.57. Share price rose 9.1% to HK$3.85 over the past week. Declared Dividend • Mar 10
Dividend of HK$0.10 announced Shareholders will receive a dividend of HK$0.10. Ex-date: 29th May 2025 Payment date: 16th June 2025 Dividend yield will be 2.8%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is covered by earnings (27% earnings payout ratio) but not covered by cash flows (134% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. EPS is expected to grow by 31% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Mar 08
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2024 results: EPS: US$0.048 (down from US$0.054 in FY 2023). Revenue: US$164.1m (up 6.6% from FY 2023). Net income: US$39.7m (down 12% from FY 2023). Profit margin: 24% (down from 29% in FY 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) missed analyst estimates by 2.9%. Revenue is forecast to grow 8.5% p.a. on average during the next 2 years, compared to a 27% growth forecast for the Medical Equipment industry in Hong Kong. Announcement • Feb 24
OrbusNeich Medical Group Holdings Limited to Report Fiscal Year 2024 Results on Mar 07, 2025 OrbusNeich Medical Group Holdings Limited announced that they will report fiscal year 2024 results on Mar 07, 2025 Valuation Update With 7 Day Price Move • Dec 05
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to HK$4.39, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 11x in the Medical Equipment industry in Hong Kong. Total loss to shareholders of 24% over the past year. Valuation Update With 7 Day Price Move • Nov 08
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to HK$4.14, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 10x in the Medical Equipment industry in Hong Kong. Total loss to shareholders of 47% over the past year. Major Estimate Revision • Aug 23
Consensus EPS estimates fall by 15% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$180.0m to US$167.1m. EPS estimate also fell from US$0.055 per share to US$0.047 per share. Net income forecast to grow 1.2% next year vs 30% growth forecast for Medical Equipment industry in Hong Kong. Consensus price target down from HK$7.02 to HK$5.45. Share price rose 2.5% to HK$3.28 over the past week. Reported Earnings • Aug 18
First half 2024 earnings released: EPS: US$0.023 (vs US$0.03 in 1H 2023) First half 2024 results: EPS: US$0.023 (down from US$0.03 in 1H 2023). Revenue: US$78.9m (down 3.1% from 1H 2023). Net income: US$18.8m (down 25% from 1H 2023). Profit margin: 24% (down from 31% in 1H 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Medical Equipment industry in Hong Kong. Announcement • Aug 06
OrbusNeich Medical Group Holdings Limited to Report First Half, 2024 Results on Aug 16, 2024 OrbusNeich Medical Group Holdings Limited announced that they will report first half, 2024 results on Aug 16, 2024 Valuation Update With 7 Day Price Move • Jul 08
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to HK$3.60, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 8x in the Medical Equipment industry in Hong Kong. Total loss to shareholders of 57% over the past year. Simply Wall St's valuation model estimates the intrinsic value at HK$6.43 per share. Announcement • Jun 08
OrbusNeich Medical Group Holdings Limited Approves Final Dividend for the Year Ended December 31, 2023, Payable on or Around June 28, 2024 OrbusNeich Medical Group Holdings Limited announced at annual general meeting held on June 6, 2024, the shareholders approved the payment of a final dividend of 10 HK cents per share out of the share premium account of the Company for the year ended December 31, 2023. The dividend expected to be distributed in cash on or around June 28, 2024 to the Shareholders whose names appear on the Company's register of members as at 4:30 p.m. on June 17, 2024, being the record date of determination of entitlements of the Final Dividend. Valuation Update With 7 Day Price Move • May 09
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to HK$4.35, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 10x in the Medical Equipment industry in Hong Kong. Total loss to shareholders of 65% over the past year. Simply Wall St's valuation model estimates the intrinsic value at HK$6.48 per share. Reported Earnings • Apr 20
Full year 2023 earnings: EPS and revenues exceed analyst expectations Full year 2023 results: EPS: US$0.054 (up from US$0.032 in FY 2022). Revenue: US$153.9m (up 13% from FY 2022). Net income: US$45.1m (up 144% from FY 2022). Profit margin: 29% (up from 14% in FY 2022). The increase in margin was primarily driven by higher revenue. Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Medical Equipment industry in Hong Kong. Reported Earnings • Mar 08
Full year 2023 earnings: EPS and revenues exceed analyst expectations Full year 2023 results: EPS: US$0.055 (up from US$0.032 in FY 2022). Revenue: US$153.9m (up 13% from FY 2022). Net income: US$45.1m (up 144% from FY 2022). Profit margin: 29% (up from 14% in FY 2022). The increase in margin was primarily driven by higher revenue. Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Medical Equipment industry in Hong Kong. Announcement • Mar 07
OrbusNeich Medical Group Holdings Limited, Annual General Meeting, Jun 06, 2024 OrbusNeich Medical Group Holdings Limited, Annual General Meeting, Jun 06, 2024. Agenda: To consider dividend. Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorates as stock falls 25% After last week's 25% share price decline to HK$3.83, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 8x in the Medical Equipment industry in Hong Kong. Total loss to shareholders of 68% over the past year. Announcement • Feb 24
OrbusNeich Medical Group Holdings Limited to Report Fiscal Year 2023 Results on Mar 07, 2024 OrbusNeich Medical Group Holdings Limited announced that they will report fiscal year 2023 results on Mar 07, 2024 Valuation Update With 7 Day Price Move • Nov 30
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to HK$6.25, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 20x in the Medical Equipment industry in Hong Kong. Simply Wall St's valuation model estimates the intrinsic value at HK$9.56 per share. Buying Opportunity • Nov 29
Now 26% undervalued after recent price drop Over the last 90 days, the stock is down 20%. The fair value is estimated to be HK$9.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last year. Earnings per share has grown by 10,579%. For the next 3 years, revenue is forecast to grow by 15% per annum. Earnings is also forecast to grow by 13% per annum over the same time period. Announcement • Nov 24
OrbusNeich Medical Group Holdings Limited (SEHK:6929) acquired Eucatech AG for €2.4 million. OrbusNeich Medical Group Holdings Limited (SEHK:6929) acquired Eucatech AG for €2.4 million on November 23, 2023. Upon completion of the acquisition, Eucatech AG will become a wholly-owned subsidiary of the Group.OrbusNeich Medical Group Holdings Limited (SEHK:6929) acquired Eucatech AG on November 23, 2023. Announcement • Sep 08
OrbusNeich Medical Group Holdings Limited Announces Retirement of Ching Chung John Chow from the Group of All Executive Roles and Has Been Re-Designated as Non-Executive Director with effect from September 7, 2023 OrbusNeich Medical Group Holdings Limited announced that Mr. Ching Chung John CHOW, an Executive Director, has retired from the Group of all executive roles and has been re-designated as a Non-executive Director with effect from September 7, 2023. Mr. Chow, aged 65, has been a Director since July 22, 2021 and was re-designated as an Executive Director on September 29, 2021. Mr. Chow was the head of business development of the Group, primarily responsible for overseeing overall business development activities of the Group prior to his retirement. Mr. Chow has around 38 years of experience in interventional cardiology. He worked in Cordis-Neich Limited in May 1984 and was promoted as the general manager in January 1991. Prior to joining the Group, he was appointed as the Asia Pacific regional marketing director of the Cordis franchise in Johnson & Johnson in June 1999. After his employment at Johnson & Johnson, Mr. Chow joined the Group in August 2000 and served as the head of sales and marketing for the Asia Pacific region from 2010 to 2015. Mr. Chow was appointed as the director of business development of the Group on May 17, 2006 and was appointed as the head of business development on September 29, 2021. Mr. Chow obtained his Bachelor of Arts degree from York University in Canada in June 1980. Reported Earnings • Aug 18
First half 2023 earnings released: EPS: US$0.03 (vs US$0.014 in 1H 2022) First half 2023 results: EPS: US$0.03 (up from US$0.014 in 1H 2022). Revenue: US$81.4m (up 18% from 1H 2022). Net income: US$25.2m (up 213% from 1H 2022). Profit margin: 31% (up from 12% in 1H 2022). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Medical Equipment industry in Hong Kong. Announcement • Aug 03
OrbusNeich Medical Group Holdings Limited to Report First Half, 2023 Results on Aug 17, 2023 OrbusNeich Medical Group Holdings Limited announced that they will report first half, 2023 results on Aug 17, 2023 Announcement • May 24
OrbusNeich Medical Group Holdings Limited Appoints Ting San Peter Lionel LEUNG as Non-Executive Director OrbusNeich Medical Group Holdings Limited announced that Mr. Ting San Peter Lionel LEUNG has been appointed as a non-executive Director with effect from the conclusion of the AGM. Valuation Update With 7 Day Price Move • May 24
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to HK$11.20, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 22x in the Medical Equipment industry in Hong Kong. Reported Earnings • Mar 09
Full year 2022 earnings: EPS exceeds analyst expectations Full year 2022 results: EPS: US$0.032 (up from US$0.008 loss in FY 2021). Revenue: US$136.8m (up 18% from FY 2021). Net income: US$18.5m (up US$22.9m from FY 2021). Profit margin: 14% (up from net loss in FY 2021). The move to profitability was primarily driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 25% growth forecast for the Medical Equipment industry in Hong Kong. Announcement • Dec 24
OrbusNeich Medical Group Holdings Limited has completed an IPO in the amount of HKD 480.7704 million. OrbusNeich Medical Group Holdings Limited has completed an IPO in the amount of HKD 480.7704 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 5,464,000
Price\Range: HKD 8.8
Discount Per Security: HKD 0.264
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 49,169,000
Price\Range: HKD 8.8
Discount Per Security: HKD 0.264
Transaction Features: Regulation S Board Change • Dec 23
Less than half of directors are independent There are 8 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). Head of Business Development & Executive Director John Chow is the most experienced director on the board, commencing their role in 2021. Independent Non-Executive Director Yip Keung Chan was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.